Gamma-PN

Phase 1Biologic

GGPN Vaccines

Gamma-PN is one of 4 biologic programs targeting Pneumococcal Disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pneumococcal DiseaseRecruiting

Pneumococcal DiseasePhase 1

Recruiting

Competition

Competitive Landscape

4 competitors in Pneumococcal Disease

#DrugCompanyPhaseTrials

Pneumococcal Vaccine

GSK

Phase 3

1 2

PG4

Pfizer

Phase 3

4 3

20vpnc

Pfizer

Phase 3

2 4

Gamma-PN

GGPN Vaccines

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Unspecified1 trial

Serum Collection Study for Assay Development

Recruiting·GGPN Vaccines·Phase 1·NCT07205289·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Gamma-PN. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Gamma-PN compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Gamma-PN. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GPN Vaccines company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: GGPN Vaccines

Gamma-PN

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Unspecified1 trial

References

Drug Info

Quick Facts

Related News